NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.78 -0.65 (-3.03 %) (As of 02/25/2020 02:08 PM ET) Add Compare Today's Range$20.65Now: $20.78▼$22.0650-Day Range$17.82MA: $19.84▼$21.8352-Week Range$14.61Now: $20.78▼$21.97Volume232,920 shsAverage Volume1.60 million shsMarket Capitalization$3.05 billionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO Previous Symbol CUSIP40637H10 CIK1159036 Webhttp://www.halozyme.com/ Phone858-794-8889Debt Debt-to-Equity Ratio0.04 Current Ratio3.17 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$151.86 million Price / Sales20.05 Cash FlowN/A Price / Cash FlowN/A Book Value$1.72 per share Price / Book12.08Profitability EPS (Most Recent Fiscal Year)($0.56) Net Income$-80,330,000.00 Net Margins-19.73% Return on Equity-15.76% Return on Assets-9.65%Miscellaneous Employees281 Outstanding Shares146,540,000Market Cap$3.05 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HALO Rates by TradingView Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.06. The biopharmaceutical company had revenue of $53.70 million for the quarter, compared to analysts' expectations of $55.69 million. Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The business's revenue was down 10.8% compared to the same quarter last year. During the same period last year, the business posted ($0.01) earnings per share. View Halozyme Therapeutics' Earnings History. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Halozyme Therapeutics. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics updated its FY20 earnings guidance on Monday, February, 24th. The company provided EPS guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.59. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.15 million. What price target have analysts set for HALO? 7 equities research analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $20.00 to $35.00. On average, they anticipate Halozyme Therapeutics' share price to reach $24.71 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics. What is the consensus analysts' recommendation for Halozyme Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics. What are Wall Street analysts saying about Halozyme Therapeutics stock? Here are some recent quotes from research analysts about Halozyme Therapeutics stock: 1. According to Zacks Investment Research, "Halozyme has promising collaboration deals related to its ENHANZE technology with several small and large pharma companies. These deals generate the majority of revenues for the company. Blockbuster drugs like Herceptin and Rituxan use ENHANZE for subcutaneous administration, which boosts Halozyme’s royalties. Development of subcutaneous formulation of another blockbuster drug, Darzalex is encouraging. Restructuring initiatives following failure of PEGPH20 is also encouraging. Halozyme’s shares have outperformed the industry so far this year. However, the company’s dependence on collaboration partners for revenues remains a concern. Rising competition for partnered drugs is also a concern. Estimates have been stable ahead of Q3 earnings. The company has a positive record of earnings surprise in the recent quarters." (11/7/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019) Has Halozyme Therapeutics been receiving favorable news coverage? News coverage about HALO stock has been trending very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Halozyme Therapeutics. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the folowing people: Dr. Helen I. Torley, Pres, CEO & Director (Age 56)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44) Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Third Security LLC (4.81%), William Blair Investment Management LLC (4.32%), Artisan Partners Limited Partnership (3.59%), State Street Corp (3.06%), Pictet Asset Management Ltd. (1.96%) and FMR LLC (1.60%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics. Which major investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Third Security LLC, Goldman Sachs Group Inc., Sofinnova Investments Inc., Jacobs Levy Equity Management Inc., Man Group plc, FMR LLC and New York State Common Retirement Fund. View Insider Buying and Selling for Halozyme Therapeutics. Which major investors are buying Halozyme Therapeutics stock? HALO stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Renaissance Technologies LLC, William Blair Investment Management LLC, Partner Fund Management L.P., Granite Investment Partners LLC, Prudential Financial Inc., Kornitzer Capital Management Inc. KS and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Halozyme Therapeutics. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $20.78. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $3.05 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics. What is Halozyme Therapeutics' official website? The official website for Halozyme Therapeutics is http://www.halozyme.com/. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected] MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 421 (Vote Outperform)Underperform Votes: 383 (Vote Underperform)Total Votes: 804MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/25/2020 by MarketBeat.com StaffFeatured Article: What is a Call Option?
